Abstract 114P
Background
Therapeutic management of locally advanced gastric cancer (LAGC) combines surgery with neo-adjuvant (NACT) and adjuvant chemotherapy (ACT). miRNAs have emerged as promising candidates for treatment efficacy prediction, hence, the present study aims at defining therapy response-specific profiles of circulating miRNAin LAGC.
Methods
A prospective cohort of 26 LAGC patients scheduled for NACT, surgery and ACT treatment was considered. Peripheral blood samples were collected prior to (preNACT) and after NACT (postNACT) as well as after tumor surgical excision and by completion of ACT (postACT). Patients were grouped according to Becker’s tumor regression grade criteria into responders (R;TRG1-2) and non-responders (NR;TRG3). Serum RNA was isolated with magnetic bead technology and relative expression levels of miR21a, mir19a, mir20a, miR30a & miR15a were determined by qRT-PCR.
Results
PreNACT profiles revealed expression differences between R and NR patient groups, with Responders characterized by elevated miR21a and, particularly, miR30a and miR15a expression levels as compared to NR. In response to NACT, miR15a & miR30a downregulation was the most distinguished difference defining Responders. R profile also showed a distinct upregulation of mir21a and elevation of the initially low levels of mir20a & mir19a. In contrast, NR showed NACT-dependent upregulation of all targets except miR19a. Interestingly, it was surgical depletion of primary tumor that first led to a marked activation of studied miRNAs in both R and NR patients, an upregulation found further augmented after ACT treatment. Nevertheless, postACT miR15a and miR30a levels in R remained substantially lower than in NR, evidence adding to their potential as chemosensitivity indicators.
Conclusions
This study aimed at monitoring the consequential to oncological and surgical therapy response-dependent expression patterns of a panel of circulating miR and, despite the small case series, revealed the potential of, particularly, miR15a and miR30a as chemosensitivity predictors in LAGC. The evidence merits further investigation in larger patient cohorts to validate their clinical utility as biomarkes for stratifying GC patients for precision therapy.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
National and Kapodistrian University of Athens, Greece.
Funding
ERAPerMed 2019-GRAMMY ERA Per Med - Joint Transnational Call for Proposals (2019) for “Personalised Medicine: Multidisciplinary Research Towards Implementation”.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
83P - Evaluation of serum macrophage inhibitory cytokine 1 as a diagnostic biomarker for pancreatic cancer: A systematic review and diagnostic accuracy meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Profiling of lipid-loaded macrophages in melanoma
Presenter: Marta Pandini
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Whole-genome CRISPR screening identifies chemosensor receptors as key regulators of the cancer-macrophage crosstalk
Presenter: Giulia Marelli
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Regulation of cancer progression through the gut microbiome and immuno-nutrition
Presenter: Anikka Swaby
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Macrophage ontogeny underlies functional programs and drives brain tumor progression
Presenter: Miranda Yu
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluating the infiltration of anti-NKG2DL CAR-T cells into a 3D cell culture developed in a Vitvo cartridge bioreactor
Presenter: Aigul Valiullina
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Neutrophils as producers of endothelial growth factor in the progression of kidney cancer
Presenter: Ilseya Myagdieva
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: A systematic review
Presenter: Omar Mubarak
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Reduction in the relative lymphocyte count as a predictive biomarker for serious immune-related adverse events in patients with metastatic non-small cell lung cancer on immunotherapy: Single institution experience
Presenter: Antoan Garev
Session: Cocktail & Poster Display session
Resources:
Abstract